Marksans Pharma reports strong half-year consolidated income, profit growth

Marksans Pharma Ltd. reported a consolidated total income from operations of INR 13,676.11 million for the half-year ended September 30, 2025, a substantial increase from INR 6,418.52 million in the prior year. The consolidated net profit after tax for the same period reached INR 1,573.41 million, up from INR 977.60 million. For the quarter ended September 30, 2025, consolidated total income was INR 7,419.81 million, with a net profit after tax of INR 991.39 million.

On a standalone basis, Marksans Pharma achieved a total income from operations of INR 7,003.74 million for the half-year ended September 30, 2025, and a net profit after tax of INR 1,478.62 million. Quarterly standalone figures showed total income at INR 3,786.30 million and net profit after tax at INR 998.06 million.

The company's earnings per equity share (face value INR 1 each) for the half-year ended September 30, 2025, stood at INR 3.45 (Basic and Diluted) on a consolidated basis, compared to INR 2.13 in the previous year. Standalone basic and diluted EPS for the half-year was INR 3.26.